SGYP Dividend History & Description — Synergy Pharmaceuticals Inc
Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. Co. is engaged in the discovery, research and development activities around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Co. discovered, is developing and controls 100% worldwide rights to its proprietary uroguanylin analog platform. Co.'s commercial product, plecanatide, under trademark name TRULANCE is for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. When considering the Synergy Pharmaceuticals Inc stock dividend history, we have taken known splits into account, such that the SGYP dividend history is presented on a split-adjusted ("apples to apples") basis. Synergy Pharmaceuticals Inc dividend history is presented both in graphical/chart form, and as a SGYP dividend history data table along the right-hand column.